Safety Study for Beta Thalassemia Subjects on PTG-300

Completed · Phase 2

Conditions studied: β-thalassemia, Ineffective Erythropoiesis

In brief

In this study will investigate long term safety and use of the PTG-300 in Beta Thalassemia patients.

Key facts

Study ID

NCT04054921

Run by

Protagonist Therapeutics, Inc.

People needed

34

Starts

2019-05-10

Expected to finish

2020-07-31

Last updated by the study team

2021-07-16

Who can join

Age: 12 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• NTD and TD β-thalassemia subjects who completed Week 12 and Week 16 respectively in Study PTG-300-02.

You may not qualify if…

• Subjects who discontinued prematurely from study 300-02 (before Week 12 in NTD and Week 16 in TD).

Where it is running

• UCSF Benioff Children's Hospital — Oakland, California, United States
• Boston Children's Hospital — Boston, Massachusetts, United States
• Laiko General Hospital of Athens — Athens, Greece
• Athens General Hospital 'G Gennimatas' — Athens, Greece
• University General Hospital of Patras — Pátrai, Greece
• Chronic Care Center — Hazmiyeh, Lebanon
• Hospital Ampang — Ampang, Malaysia
• Hospital Umum Sarawak — Kuching, Malaysia
• Siriraj Hospital Mahidol University — Bangkok, Thailand
• Khon Kaen University — Khon Kaen, Thailand
• Chulalongkorn University — Pathum Wan, Thailand
• Naresuan University — Phitsanulok, Thailand
• University Hospital Farhat Hached — Sousse, Tunisia
• Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi — Istanbul, Turkey (Türkiye)
• Ege Universitesi Tip Fakultesi — Izmir, Turkey (Türkiye)
• Barts Health NHS Trust — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.